Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Li-Wei KuoCancer Biology Training Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-1135-8740
Lyndsey S CrumpDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2790-7780
Kathleen O'NeillDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-7681-2863
Michelle M WilliamsDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-7063-9147
Jessica L ChristensonDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-6311-8191
Nicole S SpoelstraDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0009-0003-3981-5960
Micaela Kalani RoyDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-1045-6752
Amy ArgabrightDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0009-0002-1674-0997
Julie A ReiszDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-7296-4963
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-2258-6490
Meher P BoorgulaUniversity of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-4700-4140
Andrew GoodspeedUniversity of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-7055-7128
Benjamin G BitlerDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-5809-5271
Jennifer K RicherDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-9960-0991
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Training Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5M
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparitiesR01CA285446 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler, Matthew J Sikora · 2023 to 2026
$2.4M
Targeting Wnt signaling in therapy-resistant ovarian cancerR37CA261987 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler · 2021 to 2026
$2.4M
Targeting heme metabolism to initiate an immune response against breast cancer liver metastasisK99CA266748 · NCI · UNIVERSITY OF COLORADO DENVER · PI WILLIAMS, MICHELLE M · 2022 to 2023
$229k
Impact of heme catabolism on triple negative breast cancer metastasis via immune-suppressionF32CA239436 · NCI · UNIVERSITY OF COLORADO DENVER · PI WILLIAMS, MICHELLE M · 2020 to 2021
significanceTDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity. · full record | OpenQuestion